Clinical Trial Update: Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports Phase 1/2 results for a triple-drug combination (bortezomib, lenalidomide, dexamethasone) in newly diagnosed multiple myeloma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Revlimid (lenalidomide)
• Velcade (bortezomib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2014-08-19